Immunotherapy has been used mostly for B-ALL because the surface markers CD19, CD20, and CD22 are expressed only on B cells and not on hematopoietic stem cells or other tissues. The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.